Overview

Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of recombinant human heat shock protein 70-polyvalent peptide complex (HerpV) vaccine administration on recurring episodes of genital herpes by evaluating viral shedding before and after treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Agenus Inc.
Treatments:
QS 21